{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:05:53Z","timestamp":1761764753752},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1016\/j.euroneuro.2006.06.004","type":"journal-article","created":{"date-parts":[[2006,7,26]],"date-time":"2006-07-26T13:19:47Z","timestamp":1153919987000},"page":"S135-S141","source":"Crossref","is-referenced-by-count":17,"special_numbering":"S3","title":["Optimisation of long-term treatment in schizophrenia: Treating the true spectrum of symptoms"],"prefix":"10.1016","volume":"16","author":[{"given":"Siegfried","family":"Kasper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2006.06.004_bib1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1176\/appi.ajp.158.5.765","article-title":"A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder","volume":"158","author":"Conley","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.06.004_bib2","first-page":"S185","article-title":"Neurocognitive effects of aripiprazole versus olanzapine in stable psychosis","volume":"5","author":"Cornblatt","year":"2002","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2006.06.004_bib3","first-page":"1203","article-title":"From noncompliance to collaboration in the treatment of schizophrenia","volume":"41","author":"Corrigan","year":"1990","journal-title":"Hosp. Commun. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.06.004_bib4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1192\/bjp.148.2.120","article-title":"A randomised controlled trial of prophylactic neuroleptic treatment","volume":"148","author":"Crow","year":"1986","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.06.004_bib5","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","article-title":"Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis","volume":"321","author":"Geddes","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2006.06.004_bib6","doi-asserted-by":"crossref","first-page":"638","DOI":"10.4088\/JCP.v66n0515","article-title":"Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder","volume":"66","author":"Glick","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.06.004_bib7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.06.004_bib8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/oxfordjournals.schbul.a033430","article-title":"Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the \u201cright stuff\u201d?","volume":"26","author":"Green","year":"2000","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2006.06.004_bib9","doi-asserted-by":"crossref","first-page":"932","DOI":"10.4088\/JCP.v65n0709","article-title":"Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects","volume":"65","author":"Hofer","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.06.004_bib10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archpsyc.1974.01760170005001","article-title":"Drug and sociotherapy in the aftercare of schizophrenic patients: II. Two-year relapse rates","volume":"31","author":"Hogarty","year":"1974","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.06.004_bib11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0920-9964(02)00410-3","article-title":"Neurocognitive, social, and emotional dysfunction in deficit syndrome schizophrenia","volume":"65","author":"Horan","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2006.06.004_bib12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJM199601043340109","article-title":"Schizophrenia","volume":"334","author":"Kane","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2006.06.004_bib13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/15622970600685424","article-title":"Addressing the limitations of the CATIE study","volume":"7","author":"Kasper","year":"2006","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.06.004_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1017\/S1461145703003651","article-title":"Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia","volume":"6","author":"Kasper","year":"2003","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2006.06.004_bib15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1192\/bjp.164.2.141","article-title":"The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research","volume":"164","author":"Kerwin","year":"1994","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.06.004_bib16","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2006.06.004_bib17","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3109\/00048679609064999","article-title":"Depression in schizophrenia: a descriptive study","volume":"30","author":"Markou","year":"1996","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.06.004_bib18","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/0924-977X(96)00013-2","article-title":"Managing the first episode of schizophrenia: the role of new therapies","volume":"6","author":"McCreadie","year":"1996","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2006.06.004_bib19","series-title":"Abstract Presented at the 156th Annual Meeting of the American Psychiatric Association, San Francisco, CA","article-title":"Long-term weight effects of aripiprazole vs olanzapine","author":"McQuade","year":"2003"},{"key":"10.1016\/j.euroneuro.2006.06.004_bib20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.psychres.2004.02.012","article-title":"Longitudinal assessment of psychopathological domains over late-stage schizophrenia in relation to duration of initially untreated psychosis: 3-year prospective study in a long-term inpatient population","volume":"126","author":"Meagher","year":"2004","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2006.06.004_bib21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1037\/0894-4105.11.3.437","article-title":"Is it possible to be schizophrenic yet neuropsychologically normal?","volume":"11","author":"Palmer","year":"1997","journal-title":"Neuropsychology"},{"key":"10.1016\/j.euroneuro.2006.06.004_bib22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00004850-200015060-00005","article-title":"Effects of risperidone on affective symptoms in patients with schizophrenia","volume":"15","author":"Peuskens","year":"2000","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2006.06.004_bib23","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.4088\/JCP.v64n0910","article-title":"Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study","volume":"64","author":"Pigott","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.06.004_bib24","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1001\/jama.290.20.2693","article-title":"Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial","volume":"290","author":"Rosenheck","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.euroneuro.2006.06.004_bib25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0193-953X(18)30644-0","article-title":"Depression, attempted suicide, and suicide in patients with chronic schizophrenia","volume":"9","author":"Roy","year":"1986","journal-title":"Psychiatr. Clin. North Am."},{"key":"10.1016\/j.euroneuro.2006.06.004_bib26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1192\/bjp.142.5.465","article-title":"Depression in chronic schizophrenia","volume":"142","author":"Roy","year":"1983","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.06.004_bib27","first-page":"26","article-title":"Maintaining symptom control: review of ziprasidone long-term efficacy data","volume":"64","author":"Schooler","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.06.004_bib28","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/archpsyc.1997.01830170079011","article-title":"Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment","volume":"54","author":"Schooler","year":"1997","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.06.004_bib29","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1176\/appi.ajp.162.8.1535","article-title":"Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia","volume":"162","author":"Simpson","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.06.004_bib30","series-title":"Abstract Presented at the 156th Annual Meeting of the American Psychiatric Association, San Francisco, CA","article-title":"Long-term effects of aripiprazole on affective symptoms of schizophrenia","author":"Stock","year":"2003"},{"key":"10.1016\/j.euroneuro.2006.06.004_bib31","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/archpsyc.55.3.250","article-title":"Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol","volume":"55","author":"Tollefson","year":"1998","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2006.06.004_bib32","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00004714-199710000-00010","article-title":"Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders","volume":"17","author":"Tran","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2006.06.004_bib33","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/00005053-200008000-00007","article-title":"Do specific neurocognitive deficits predict specific domains of community function in schizophrenia?","volume":"188","author":"Velligan","year":"2000","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.euroneuro.2006.06.004_bib34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1023\/A:1025499131905","article-title":"Assessment and treatment selection for \u201crevolving door\u201d inpatients with schizophrenia","volume":"68","author":"Weiden","year":"1997","journal-title":"Psychiatr. Q."},{"key":"10.1016\/j.euroneuro.2006.06.004_bib35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00131746-200101000-00005","article-title":"Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications","volume":"7","author":"Weiden","year":"2001","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.euroneuro.2006.06.004_bib36","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1097\/00004850-199709004-00006","article-title":"Cognitive function in schizophrenia","volume":"12","author":"Weinberger","year":"1997","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2006.06.004_bib37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1017\/S146114570500516X","article-title":"A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia","volume":"8","author":"Woodward","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X06001088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X06001088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T08:16:06Z","timestamp":1555748166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X06001088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":37,"alternative-id":["S0924977X06001088"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2006.06.004","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}